Monday, March 2

5:00 p.m7:00 p.m.	WELCOME AND OPENING KEYNOTE LECTURES Legends 1-4
	Introductions by Cory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, NY, and Calvin J. Kuo, Stanford University, Stanford, CA
5:00 p.m6:00 p.m.	Modeling and understanding tumor biologic mechanisms Ronald A. DePinho, The University of Texas MD Anderson Cancer Center, Houston, TX
6:00 p.m7:00 p.m.	Title to be announced Toshiro Sato, Keio University, Tokyo, Japan

7:00 p.m.-9:00 p.m. OPENING RECEPTION Encore

Tuesday, March 3

7:00 a.m8:00 a.m.	BREAKFAST Encore
8:00 a.m10:00 a.m.	PLENARY SESSION 1: LINEAGE PLASTICITY, STEM CELLS AND DEVELOPMENTAL PATHWAYS Legends 1-4
	Session Chairs: Karuna Ganesh, Memorial Sloan Kettering Cancer Institute, New York, NY, and Elena Piskounova, Weill Cornell Medicine, New York, NY
8:00 a.m8:30 a.m.	Neuroendocrine differentiation in prostate development and cancer Michael M. Shen, Columbia University, New York, NY
8:30 a.m8:45 a.m.	Developmental reprogramming via Hedgehog pathway activation in nonmyogenic endothelial progenitors drives fusion-negative rhabdomyosarcoma* Mark Hatley, St. Jude Children's Research Hospital, Memphis, TN
8:45 a.m9:15 a.m.	Stem cells: Coping with stress and cancer Elaine Fuchs, Rockefeller University, New York, NY

9:15 a.m9:30 a.m.	Matched metastatic pancreatic ductal adenocarcinoma biopsies and organoid models reveal tumor cell transcriptional plasticity and subtype-specific microenvironmental crosstalk* Peter Winter, Massachusetts Institute of Technology, Cambridge, MA
9:30 a.m10:00 a.m.	Signaling networks in small-cell lung cancer Julien Sage, Stanford University, Stanford, CA
10:00 a.m10:30 a.m.	BREAK Abbey Road
10:30 a.m12:30 p.m.	PLENARY SESSION 2: MODELING THE IMMUNE RESPONSE AND THE TUMOR MICROENVIRONMENT Legends 1-4
	Session Chairs: Alison Taylor, Columbia University Medical Center, New York, NY, and Camila Dos Santos, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
10:30 a.m11:00 a.m.	The tissue-specific microenvironment in primary tumors and metastases Zena Werb, University of California San Francisco, San Francisco, CA
11:00 a.m11:15 a.m.	Use of CRISPR knock-out screen to identify genes that regulate tumor cell sensitivity to NK cell-based immunotherapy* Davide Bernareggi, University of California San Diego, San Diego, CA
11:15 a.m11:45 a.m.	Targeting the pancreas cancer microenvironment to therapeutic advantage Sunil R. Hingorani, Fred Hutchinson Cancer Research Center, Seattle, WA
11:45 a.m12:00 p.m.	Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immunosuppression* Nathan Reticker-Flynn, Stanford University, Stanford, CA
12:00 p.m12:30 p.m.	Organoid modeling of tumor and tissue microenvironments Calvin J. Kuo, Stanford University, Stanford, CA
12:30 p.m2:30 p.m.	LUNCH ON OWN
2:30 p.m4:30 p.m.	PLENARY SESSION 3: MODELING DRUG SENSITIVITY AND ADAPTIVE RESPONSE Legends 1-4
	Session Chairs: Hariharan Easwaran, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, and Jesse Boehm, Broad Institute, Cambridge, MA
2:30 p.m3:00 p.m.	Tumor organoid cultures as a platform for functional genomics Mathew Garnett, Wellcome Sanger Institute, Cambridge, United Kingdom

3:00 p.m3:15 p.m.	A metabolomics discovery profiling approach identifies an E2F1-associated purine synthesis pathway as a major component of the MET-DNA damage response network* Michaela Medová, Bern University Hospital, Bern, Switzerland
3:15 p.m3:45 p.m.	Modeling sensitivity and resistance to systemic therapies in lung cancer Katerina A. Politi, Yale University, New Haven, CT
3:45 p.m4:00 p.m.	An in vivo KRAS allelic series reveals distinct phenotypes of common oncogenic variants* Maria Paz Zafra, Weill Cornell Medicine, New York, NY
4:00 p.m4:30 p.m.	The use of GEM tumor models to identify effective therapies against KRAS mutant tumors Mariano Barbacid, CNIO, Madrid, Spain
4:30 p.m4:40 p.m.	POSTER HIGHLIGHTS A Legends 1-4
	Introductions by Cory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, NY
4:30 p.m4:32 p.m.	Modeling the tissue-specific oncogenesis of mutant RAS Amanda Moore, Genentech, Inc., South San Francisco, CA
4:32 p.m4:34 p.m.	Androgen receptor blockade induces reprogramming to mesenchymal and stemlike prostate cancer and dependency on HER2/3 signaling Hyunho Han, The University of Texas MD Anderson Cancer Center, Houston, TX
4:34 p.m4:36 p.m.	Coordinate translational control of KRAS signaling pathway in pancreatic adenocarcinoma Kamini Singh, Memorial Sloan Kettering Cancer Center, New York, NY
4:36 p.m4:38 p.m.	A new somatic engineering-based model of small-cell lung cancer development Kwon-Sik Park, University of Virginia, Charlottesville, VA
4:38 p.m4:40 p.m.	Strategies to improve engineering cancer-associated SNVs with base editing Alyna Katti, Weill Cornell Medicine, New York, NY
4:40 p.m7:00 p.m.	RECEPTION / POSTER SESSION A

Encore/Legends 5-6

Wednesday, March 4

7:00 a.m8:00 a.m.	BREAKFAST Encore
8:00 a.m10:00 a.m.	PLENARY SESSION 4: MODELING TUMOR EVOLUTION Legends 1-4
	Session Chairs: Katerina A. Politi, Yale University, New Haven, CT, and Kwon-Sik Park, University of Virginia, Charlottesville, VA
8:00 a.m8:30 a.m.	From mouse to man: Dissecting cancer mechanisms using mouse models Cory Abate-Shen, Columbia University, New York, NY
8:30 a.m8:45 p.m.	Somatic tissue engineering in mouse models reveals an actionable role for WNT pathway alterations in prostate cancer metastasis* Josef Leibold, Memorial Sloan Kettering Cancer Center, New York, NY
8:45 a.m9:15 a.m.	Identification, validation and therapeutic targeting of a driver gene in poor- prognosis breast cancer Yibin Kang, Rutgers University, Princeton, NJ
9:15 a.m9:30 a.m.	Leveraging single-cell epigenomics to uncover regulatory programs in lung adenocarcinoma* Lindsey LaFave, Massachusetts Institute of Technology, Cambridge, MA
9:30 a.m10:00 a.m.	Deconstructing the origins of PDAC development Laura D. Attardi, Stanford University School of Medicine, Stanford, CA
10:00 a.m10:30 a.m.	BREAK Abbey Road
10:30 a.m12:00 p.m.	MODEL FIDELITY FORUM Legends 1-4
	Moderator: Pier Paolo Pandolfi, Dana-Farber Cancer Center, Boston, MA
	Embracing complexity: Changing how we use the mouse to model human cancer Carol Bult, The Jackson Laboratory, Bar Harbor, ME
	The International Human Cancer Models Initiative is generating models annotated with clinical and molecular data Daniela S. Gerhard, National Cancer Institute, Bethesda, MD
	A systematic approach to create patient-derived models of rare tumors* Jesse Boehm, Broad Institute, Cambridge, MA

12:00 p.m1:00 p.m.	SECOND KEYNOTE LECTURE Legends 1-4
	Introduction by Andrea Califano, Columbia University Medical Center, New York, NY
	Defining cancer dependency maps William C. Hahn, Dana-Farber Cancer Center, Boston, MA
1:00 p.m1:10 p.m.	POSTER HIGHLIGHTS B Legends 1-4
	Introductions by Cory Abate-Shen, Columbia University Irving Comprehensive Cancer Center, New York, NY
1:00 p.m1:02 p.m.	The zebrafish as a mechanical filter: Using zebrafish xenografts to model Ewing sarcoma metastasis in vivo Dagan Segal, The University of Texas Southwestern Medical Center, Dallas, TX
1:02 p.m1:04 p.m.	Impact of genetic diversity on the growth of human-derived xenografts Muneer Hasham, The Jackson Laboratory, Bar Harbor, ME
1:04 p.m1:06 p.m.	A hierarchical model of DNA repair inferred from omics-scale genetic interaction data reveals the dynamics of DNA damage induction Anton Kratz, University of California San Diego, San Diego, CA
1:06 p.m1:08 p.m.	Predictive modeling, applied to genetically engineered mouse models of breast or lung cancer, provides insights into major oncogenic pathways Bodo Lange, Alacris Theranostics GmbH, Berlin, Germany
1:08 p.m1:10 p.m.	Mechanism-based computational models to study interplay between EGFR inhibitors and KRAS mutants Edward Stites, Salk Institute for Biological Studies, La Jolla, CA
1:10 p.m3:30 p.m.	LUNCH / POSTER SESSION B Encore/Legends 5-6
3:30 p.m5:15 p.m.	PLENARY SESSION 5: FROM MODELS TO THE CLINIC Legends 1-4
	Session Chairs: Jinsong Liu, The University of Texas MD Anderson Cancer Center, Houston, TX, and Michael Shen, Columbia University Medical Center, New York, NY
3:30 p.m4:00 p.m.	Genetic dissection of breast cancer development and therapy resistance in mouse models Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands
4:00 p.m4:15 p.m.	A versatile ES cell-based melanoma mouse modeling platform* Florian Karreth, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

4:15 p.m4:30 p.m.	MADR: Rapid generation of somatic mosaics with locus-specific, stably integrated transgenic elements for generation of "personalized" mouse models and human organoid tumor models* Joshua Breunig, Cedars-Sinai Medical Center, Los Angeles, CA
4:30 p.m5:00 p.m.	Role of autophagy in cancer metabolism Eileen P. White, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
5:00 p.m5:15 p.m.	Dynamic single-cell imaging of human cancer growth and therapy responses following engraftment into immunodeficient zebrafish* David Langenau, Massachusetts General Hospital Research Institute, Charlestown, MA
5:15 p.m5:45 p.m.	Modeling cancer in the mouse and its therapeutic implications Pier Paolo Pandolfi, Dana-Farber Cancer Center, Boston, MA
5:45 p.m.	DINNER ON OWN
Thursday, March 5	
7:00 a.m8:00 a.m.	BREAKFAST Encore

8:00 a.m10:00 a.m.	PLENARY SESSION 6: SYSTEMS APPROACHES TO INTERROGATING DATA FROM MODELS Legends 1-4
	Session Chairs: Andrew White, Cornell University, Ithaca, NY, and Andrea Ventura, Sloan Kettering Institute, New York, NY
8:00 a.m8:30 a.m.	Elucidating and targeting mechanisms of single-cell state maintenance: From N-of- 1 to N-of-1-of-1 studies Andrea Califano, Columbia University Medical School, New York, NY
8:30 a.m8:45 a.m.	Polymerase-mediated ultramutagenesis: A new approach for modeling the high mutational load of human cancer* Diego Castrillon, UT Southwestern Medical Center, Dallas, TX
8:45 a.m9:15 a.m.	Systems approach to rational combination therapy Gordon B. Mills, Oregon Health and Science University Knight Cancer Institute, Portland, OR
9:15 a.m9:30 a.m.	A multiscale map of recurrently mutated systems in cancer* Fan Zheng, University of California San Diego, San Diego, CA

9:30 a.m10:00 a.m.	Single-cell-resolution lineage tracing of tumors in a mouse xenograft model reveals rapid and multidirectional metastasis Jonathan S. Weissman, University of California San Francisco, San Francisco, CA
10:00 a.m10:30 a.m.	BREAK Abbey Road
10:30 a.m12:30 p.m.	PLENARY SESSION 7: LOOKING TO THE FUTURE OF CANCER MODELING Legends 1-4
	Session Chair: Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands
10:30 a.m11:00 a.m.	Interrogating therapy response and resistance in engineered preclinical models Lukas E. Dow, Weill Cornell Medicine, New York, NY
11:00 a.m11:30 a.m.	Modeling cancer in the CRISPR era Andrea Ventura, Sloan Kettering Institute, New York, NY
11:30 a.m12:00 p.m.	Multiplexed functional cancer genomics Monte M. Winslow, Stanford University, Stanford, CA
12:00 p.m12:30 p.m.	Title to be announced Tyler Jacks, The Koch Institute of MIT, Cambridge, MA
12:30 p.m.	CLOSING REMARKS Legends 1-4
	Jos Jonkers, Netherlands Cancer Institute, Amsterdam, The Netherlands